Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13212565 | 0.76 | PDE10A (0.35) | PDE10ASLC6A3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL178406 | 0.76 | — | — | |
| SCHEMBL289897 | 0.75 | HDAC8 (0.40) | PDE10ASLC6A3NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29919997 | 0.74 | CYP2A6 (0.41) | PDE10ASLC6A3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1911589 | 0.74 | SLC6A3 (0.38) | SLC6A3NPC1RAB9ASMN1; SMN2PARP15 | |
| SCHEMBL10204766 | 0.73 | L3MBTL1 (0.46) | RAB9ACA2TDP1LMNA | |
| SCHEMBL2256863 | 0.72 | — | — | |
| SCHEMBL17085964 | 0.71 | — | — | |
| SCHEMBL105278 | 0.71 | SLC6A3 (0.39) | PDE10ASLC6A3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13412533 | 0.71 | SLC6A3 (0.36) | SLC6A3NPC1RAB9ASMN1; SMN2PARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220119386-A1 | FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20210163478-A1 | FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2021-06-03 | — | — | US | disclosed |
| US-8865708-B2 | Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-10-21 | — | — | US | disclosed |
| US-20110288082-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-11-24 | — | — | US | disclosed |
| US-20110288082-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-11-24 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119386-A1 | FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | FGFR4, FGFR1, FGFR3 | PDE10A 4100/4885SLC6A3 1845/4885NPC1 790/4885 |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | PDE10A 2187/4885SLC6A3 156/4885NPC1 458/4885 |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | PDE10A 2346/4885SLC6A3 2308/4885NPC1 2773/4885 |
| US-20110288082-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | VCP, PSMG3, PSMB3 | PDE10A 4199/4885SLC6A3 3869/4885NPC1 516/4885 |
| US-20210163478-A1 | FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | FGFR4, FGFR1, FGFR3 | PDE10A 4100/4885SLC6A3 1845/4885NPC1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.